期刊文献+

单纯前列腺上皮内瘤临床和病理特征分析——附23例报告 被引量:6

Analysis on the clinical and pathological characteristics of simple prostatic intraepithelial neoplasia.
下载PDF
导出
摘要 目的:探讨单纯前列腺上皮内瘤(prostatic intraep ithelial neop lasia,PIN)的临床和病理特征。方法:对23例低度(PIN 1级)PIN(低度组)和8例高度(PIN 2~3级)PIN(高度组)的临床资料进行数理分析,并以同期确诊为前列腺癌、BPH患者作为对照,分析上述各组患者临床和病理特征的差异。结果:高度组的血清总前列腺特异性抗原水平与低度组及BPH组比较差异均有统计学意义(均为P〈0.05)、前列腺特异性抗原密度与低度组比较差异有统计学意义(P〈0.05)。前列腺癌组的总前列腺特异性抗原、游离前列腺特异性抗原水平,前列腺体积及前列腺特异性抗原密度与其他3组比较差异均有统计学意义(P〈0.05~0.01)。免疫组织化学结果示低度PIN的特征类似于BPH而与前列腺癌有所不同,而少数(1/16)高度PIN患者的肿瘤标志物p504 s呈阳性。结论:低度PIN的临床和病理特征与BPH相似,而高度PIN的临床和病理方面具有一定的前列腺恶性肿瘤特征,需要积极进行临床追踪观察。 Objective: To study the clinical and pathological characteristics of simple prostatic intraepithelial neoplasia (PIN) . Methods: Clinical data of 23 patients with low grade prostatic intraepithelial neoplasia ( LGPIN group) and 8 patients with high grade prostatic intraepithelial neoplasia ( HGPIN group) were collected and analyzed retrospectively, and compared with the data of the patients with final diagnosis of prostatic carcinoma (PC group) or benign prostatic hyperplasia (BPH group) . Results: The level of serum total prostate specific antigen (tPSA) was statistically different between HGPIN group and LGPIN group or BPH group (P 〈 0. 05) . The prostate specific antigen density (PSAD) was statistically different between HGPIN group and LGPIN group (P 〈 0.05 ) . The data including the level of tPSA and free prostate specific antigen, the volume of prostate and PSAD were statistically different between PC group and the other groups ( P 〈 0. 05~ 0. 01 ) . According to the immunohistochemical report, the characteristics of LGPIN group were similar to that of BPH but PC group. The tumor marker p504s was found to be positive in one patient with HGPIN. Conclusion: The clinical and pathological characteristics of LGPIN are similar to that of BPH. HGPIN has some clinical and pathological characteristics of PC. The patients with HGPIN need follow-up actively.
出处 《新医学》 北大核心 2008年第2期80-82,共3页 Journal of New Medicine
关键词 前列腺癌 前列腺上皮内瘤 良性前列腺增生 前列腺特异性抗原 免疫组织化学 Prostatic carcinoma Prostatic intraepithelial neoplasia Benign prostatic hyperplasia Prostate specific antigen Immunohistochemistry
  • 相关文献

参考文献6

  • 1HELPAP B. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens[J]. Virchows Arch, 2006, 448 (4) : 480- 484.
  • 2LOEB S, GONZALEZ C M, ROEHL K A, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening[J]. J Urol, 2006, 175 (3 Pt 1 ) : 902- 906.
  • 3方友强,高新.生物标记物早期诊断前列腺癌的研究进展[J].新医学,2005,36(5):309-310. 被引量:3
  • 4YANG W J, LEE D H, CHUNG B H, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study[ J ]. Urology, 2006, 67 (2) : 333-336.
  • 5DE MATTEIS M, POGGI C, DE MARTINO A, et al. Repeat biopsy in patients with initial diagnosis of PIN [ J]. Radiol Med (意大利文),2005,110(3):190-198.
  • 6KAWAI M, OKAJIMA K, KOBAYASHI K, et al. Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations [ J ]. Hinyokika Kiyo (日文 ), 2006, 52 (2): 113-117.

二级参考文献23

  • 1肖雨,陈杰,罗玉凤,曹金玲,凌庆,金锋.前列腺腺癌中P504S的检测及意义[J].中华医学杂志,2004,84(16):1362-1366. 被引量:16
  • 2Martel CL, Gumerlock PH, Meyers FJ, et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev,2003, 29 (3): 171-187.
  • 3Hessels D, Verhaegh GW, Schalken JA, et al. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn, 2004, 4 (4): 513-526.
  • 4Graner LS, Lawler KD, Marignca JL, et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM'protein in the LNCaP prostatic carcinoma cell line. Cancer Res, 1998, 58(21): 4787-4789.
  • 5Basso D, Fogar MG, Piva MG, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology, 2000, 55 (5): 710-715.
  • 6Chu DC, Chuang CK, Liou YF, et al. The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. Ann N Y Acad Sci, 2004, 1022 (4):157-162.
  • 7Nam RK, Dianeondis EP, Toi A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol, 2000, 18 (5):1036-1042.
  • 8Magklara A, Scorilas A, Catalona WJ, et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic byperplasia in patients with moderately increased total PSA. Clin Cbem, 1999, 45 ( 11 ) :1961-1966.
  • 9Kwiatkowski MK, Recker F, Piiromen T, et al. In prdstatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA4 to 10 ng/mL Urology, 1998, 52 (3) : 360-365.
  • 10Vaisanen V, Efikssen S, Ivaska KK, et al. Development of sensitive immunoassays for free and total human glandular kalfikrein 2. Clin Chem,2004, 50 (9): 1607-1617.

共引文献2

同被引文献45

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部